$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

$hbio Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000117184315004444 Filed on August 06, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$28.80M	$26.96M
YoY Change	6.83%	3.31%
Cost Of Revenue	$16.21M	$14.68M
YoY Change	10.39%	4.82%
Gross Profit	$12.60M	$12.28M
YoY Change	2.58%	1.56%
Gross Profit Margin	43.73%	45.54%
Selling, General & Admin	$10.05M	$8.554M
YoY Change	17.49%	-2.26%
% of Gross Profit	79.79%	69.67%
Research & Development	$1.714M	$1.284M
YoY Change	33.49%	39.26%
% of Gross Profit	13.61%	10.46%
Depreciation & Amortization	$1.090M	$910.0K
YoY Change	19.78%	-9.0%
% of Gross Profit	8.65%	7.41%
Operating Expenses	$12.50M	$10.54M
YoY Change	18.56%	-7.08%
Operating Profit	$99.00K	$1.738M
YoY Change	-94.3%	132.98%
Interest Expense	$215.0K	$248.0K
YoY Change	-13.31%	1.22%
% of Operating Profit	217.17%	14.27%
Other Income/Expense, Net	-$526.0K	-$468.0K
YoY Change	12.39%	41.82%
Pretax Income	-$427.0K	$1.270M
YoY Change	-133.62%	205.29%
Income Tax	-$776.0K	$248.0K
% Of Pretax Income		19.53%
Net Earnings	$349.0K	$1.022M
YoY Change	-65.85%	-649.46%
Net Earnings / Revenue	1.21%	3.79%
Basic Earnings Per Share	$0.01	$0.03
Diluted Earnings Per Share	$0.01	$0.03
COMMON SHARES
Basic Shares Outstanding	33.57M shares	32.05M shares
Diluted Shares Outstanding	35.03M shares	32.95M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.400M	$26.40M
YoY Change	-71.97%	-22.58%
Cash & Equivalents	$6.090M	$26.43M
Short-Term Investments
Other Short-Term Assets	$4.922M	$1.900M
YoY Change	159.05%	26.67%
Inventory	$23.07M	$17.20M
Prepaid Expenses
Receivables	$18.54M	$14.30M
Other Receivables	$5.000M	$4.600M
Total Short-Term Assets	$56.54M	$64.40M
YoY Change	-12.2%	-11.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.764M	$4.100M
YoY Change	40.59%	-6.82%
Goodwill	$41.08M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$406.0K	$13.40M
YoY Change	-96.97%	8.06%
Total Long-Term Assets	$82.04M	$73.30M
YoY Change	11.92%	0.14%
TOTAL ASSETS
Total Short-Term Assets	$56.54M	$64.40M
Total Long-Term Assets	$82.04M	$73.30M
Total Assets	$138.6M	$137.7M
YoY Change	0.64%	-5.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.834M	$5.100M
YoY Change	73.22%	4.08%
Accrued Expenses	$4.438M	$4.600M
YoY Change	-3.52%	21.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.000M	$5.000M
YoY Change	0.0%	66.67%
Total Short-Term Liabilities	$21.23M	$16.40M
YoY Change	29.47%	23.31%
LONG-TERM LIABILITIES
Long-Term Debt	$15.65M	$17.30M
YoY Change	-9.54%	-18.78%
Other Long-Term Liabilities	$4.700M	$5.700M
YoY Change	-17.54%	-1.72%
Total Long-Term Liabilities	$15.65M	$23.00M
YoY Change	-31.96%	-15.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.23M	$16.40M
Total Long-Term Liabilities	$15.65M	$23.00M
Total Liabilities	$43.76M	$39.50M
YoY Change	10.79%	-2.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.74M
YoY Change
Common Stock	$210.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	7.746M shares
Shareholders Equity	$94.81M	$98.20M
YoY Change
Total Liabilities & Shareholders Equity	$138.6M	$137.7M
YoY Change	0.64%	-5.68%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	$349.0K	$1.022M
YoY Change	-65.85%	-649.46%
Depreciation, Depletion And Amortization	$1.090M	$910.0K
YoY Change	19.78%	-9.0%
Cash From Operating Activities	-$480.0K	$1.420M
YoY Change	-133.8%	77.5%
INVESTING ACTIVITIES
Capital Expenditures	-$600.0K	-$460.0K
YoY Change	30.43%	58.62%
Acquisitions
YoY Change
Other Investing Activities	$20.00K	-$30.00K
YoY Change	-166.67%
Cash From Investing Activities	-$580.0K	-$500.0K
YoY Change	16.0%	72.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	200.0K	-570.0K
YoY Change	-135.09%	-105.88%
NET CHANGE
Cash From Operating Activities	-480.0K	1.420M
Cash From Investing Activities	-580.0K	-500.0K
Cash From Financing Activities	200.0K	-570.0K
Net Change In Cash	-860.0K	350.0K
YoY Change	-345.71%	-96.57%
FREE CASH FLOW
Cash From Operating Activities	-$480.0K	$1.420M
Capital Expenditures	-$600.0K	-$460.0K
Free Cash Flow	$120.0K	$1.880M
YoY Change	-93.62%	72.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	863000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	-246055	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.01
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6263112	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5169376	shares
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3.42
CY2015Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3.87
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	323894	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.04
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	306397	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	-237188	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.3
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.3
	hbio	Stock Issued During Period Gross Stock Options Exercised StockIssuedDuringPeriodGrossStockOptionsExercised	1710681	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.56
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4108	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0172	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5683	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0178	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M0D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	919000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1272000	USD
CY2015Q2	hbio	Percentage Of Outstanding Common Stock PercentageOfOutstandingCommonStock	0.2	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate	0.85	pure
CY2015Q2	hbio	Employee Stock Purchase Plan Shares Authorized EmployeeStockPurchasePlanSharesAuthorized	750000	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	611369	shares
CY2015Q2	hbio	Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold LenderApprovalToFundAcquisitionWithCashPromissoryNoteInExcessOfThreshold	6000000	USD
CY2015Q2	hbio	Lender Approval To Fund Acquisition With Equity In Excess Of Threshold LenderApprovalToFundAcquisitionWithEquityInExcessOfThreshold	10000000	USD
	dei	Trading Symbol TradingSymbol	HBIO
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40308763	shares
	us-gaap	Gross Profit GrossProfit	24073000	USD
CY2015Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16205000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2009Q3	hbio	Previous Approved Credit Facility PreviousApprovedCreditFacility	20000000	USD
CY2013Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000	USD
CY2013Q1	hbio	Ddtl Threshold For Dollar For Dollar Reduction In Revolving Line DdtlThresholdForDollarForDollarReductionInRevolvingLine	10000000	USD
CY2009Q3	hbio	Interest Rate In Excess Of Libor On Credit Facility InterestRateInExcessOfLiborOnCreditFacility	0.03	pure
CY2015Q2	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	8500000	USD
CY2013Q4	hbio	Transferof Delayed Draw Down Term Loan Capacity To Revolver Capacity TransferofDelayedDrawDownTermLoanCapacityToRevolverCapacity	5000000	USD
	us-gaap	Derivative Instruments Gain Loss Reclassification From Accumulated Oci To Income Estimated Net Amount To Be Transferred DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred	100000	USD
	hbio	Derivative Interest Rate Swap Effective Percentage DerivativeInterestRateSwapEffectivePercentage	1	pure
CY2014Q2	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	41000	USD
CY2015Q2	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	44000	USD
CY2014Q2	hbio	Transition Services Charged To Spinnee TransitionServicesChargedToSpinnee	41000	USD
CY2014Q2	hbio	Distribution Revenues From Spinnee DistributionRevenuesFromSpinnee	31000	USD
CY2015Q2	hbio	Distribution Revenues From Spinnee DistributionRevenuesFromSpinnee	101000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16141000	USD
CY2014Q4	us-gaap	Assets Assets	135916000	USD
CY2014Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1252000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4742000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	20531000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	11056000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21153000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	864000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	1515000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	57063000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	380000	USD
CY2014Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	5000000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6294000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	655000	USD
CY2014Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	554000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4452000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1023000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18099000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16450000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1325000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	4574000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	40448000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	397000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	206656000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92684000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8233000	USD
CY2014Q4	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	135916000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18542000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	2608000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	4922000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	56542000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5764000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	11018000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22538000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	41081000	USD
CY2015Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1228000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	406000	USD
CY2015Q2	us-gaap	Assets Assets	138577000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	23068000	USD
CY2015Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	5000000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8834000	USD
CY2015Q2	us-gaap	Revenues Revenues	28800000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	12595000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	12496000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	99000	USD
CY2015Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	159000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4438000	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1692000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21233000	USD
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15650000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2206000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	4675000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	43764000	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	415000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	209793000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93736000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10991000	USD
CY2015Q2	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138577000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	320000	USD
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41661261	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33915754	shares
CY2014Q4	us-gaap	Goodwill Goodwill	39822000	USD
CY2014Q4	us-gaap	Secured Debt SecuredDebt	21450000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14134000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7402000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	95468000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	94813000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	30490000	USD
	us-gaap	Operating Expenses OperatingExpenses	25124000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1051000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1140000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-526000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2191000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-427000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1139000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1052000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Revenues Revenues	52851000	USD
CY2014Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14680000	USD
	us-gaap	Gross Profit GrossProfit	24039000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	12278000	USD
	us-gaap	Operating Expenses OperatingExpenses	20967000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	10540000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	3072000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1738000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-783000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-468000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2289000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1270000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	548000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	248000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	1022000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
	us-gaap	Net Income Loss NetIncomeLoss	1741000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33240467	shares
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1272000	USD
CY2014Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	587000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-776000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	349000	USD
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2014Q2	us-gaap	Revenues Revenues	26958000	USD
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2015Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	246000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	121000	USD
CY2014	hbio	Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed	0.5	pure
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31946654	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	988801	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33240467	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32935455	shares
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5190000	USD
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33925864	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HARVARD BIOSCIENCE INC
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
CY2015Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5128000	USD
CY2014Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4557000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4922000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3997000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1714000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1284000	USD
CY2015Q2	us-gaap	Restructuring Charges RestructuringCharges	54000	USD
CY2014Q2	us-gaap	Restructuring Charges RestructuringCharges	115000	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	678000	USD
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-134000	USD
CY2014Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-67000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	215000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	248000	USD
CY2015Q2	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	3000	USD
CY2014Q2	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	12000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-180000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-165000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	919000	USD
	us-gaap	Depreciation Depreciation	769000	USD
	us-gaap	Depreciation Depreciation	608000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-11000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	4000	USD
	hbio	Non Cash Restructuring Charge NonCashRestructuringCharge	-64000	USD
	hbio	Non Cash Restructuring Charge NonCashRestructuringCharge	-118000	USD
	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	24000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	30000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	30000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-7000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-660000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2451000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	349000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-395000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1027000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	119000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2136000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	294000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1242000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1312000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	240000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	864000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	51000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	216000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-36000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-396000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	89000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-981000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2486000	USD
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	-1640000	USD
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	-744000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	78000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4545000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6170000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-666000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4050000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4850000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1864000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1001000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1032000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1499000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-613000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	342000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6732000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	663000	USD
	us-gaap	Interest Paid InterestPaid	427000	USD
	us-gaap	Interest Paid InterestPaid	458000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	312000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	688000	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10607000	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1256000	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	11205000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21469000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15705000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.531	pure
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1631000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1539000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1511000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1315000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1315000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	4502000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11813000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2800000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2800000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2500000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2400000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2200000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1760000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	369000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-12000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-56000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-24000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-34000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2121000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	885000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	48186000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-25648000	USD
CY2015Q2	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	42309000	USD
CY2015Q2	hbio	Total Intangible Assets TotalIntangibleAssets	90495000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2061000	USD
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-802000	USD
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Current Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInCurrentFiscalYear	400000	USD
CY2015Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	4600000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	252000	USD
CY2014Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	4400000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	0	USD
CY2014Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	-8000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	190000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	227000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	179000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	167000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-81000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-46000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	USD
CY2014Q2	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	USD
CY2015Q2	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	92000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	98000	USD
CY2014	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	-102000	USD
CY2014	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	49000	USD
CY2015Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	157000	USD
	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	-25000	USD
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	-73000	USD
CY2014	hbio	Warranty Other WarrantyOther	0	USD
	hbio	Warranty Other WarrantyOther	3000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25771000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26434000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001123494
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-2808000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-50000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2758000	USD
CY2015Q2	us-gaap	Secured Debt SecuredDebt	20650000	USD
CY2014Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.195	pure
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20200000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15010000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10138000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	946000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	9447000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10327000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8989000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9753000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8248000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3462000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2257000	USD
	us-gaap	Restructuring Charges RestructuringCharges	111000	USD
	us-gaap	Restructuring Charges RestructuringCharges	252000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1471000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1221000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	89000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-148000	USD
	us-gaap	Interest Expense InterestExpense	437000	USD
	us-gaap	Interest Expense InterestExpense	513000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	4000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	26000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-796000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-148000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	400000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2737000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	584000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-71000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-80000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-50000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-69000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3810000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1830000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2015Q2	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	200000	USD
CY2014Q2	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	200000	USD
	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	800000	USD
	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	200000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	45638000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-24485000	USD
CY2014Q4	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	41074000	USD
CY2014Q4	hbio	Total Intangible Assets TotalIntangibleAssets	86712000	USD
	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	86000	USD
	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	81000	USD
	hbio	Distribution Revenues From Spinnee DistributionRevenuesFromSpinnee	149000	USD
	hbio	Distribution Revenues From Spinnee DistributionRevenuesFromSpinnee	109000	USD
CY2013Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	305000	USD
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	0	USD
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	0	USD
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	367000	USD
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	448000	USD
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	345000	USD
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	330000	USD
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-156000	USD
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-91000	USD
	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	USD
	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	USD
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	178000	USD
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	209000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	400000	USD
CY2014Q2	hbio	Fair Value Impairment Of Pension Assets FairValueImpairmentOfPensionAssets	600000	USD
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	800000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	USD
	hbio	Estimated Rental Expenses Current Year EstimatedRentalExpensesCurrentYear	2200000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	484000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	484000	USD
	hbio	Transition Services Charged To Spinnee TransitionServicesChargedToSpinnee	101000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	254685	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3935	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5716	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018	pure
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M10D
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M14D
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	692000	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	472000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33569180	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32045314	shares
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1456470	shares
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	900618	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35025650	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32945932	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.239	pure
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div><p style='text-align:left;margin-top:9pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0pt;' >2</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' >.</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' > Recently Issued Accounting Pronouncements</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Calibri;font-size:11pt;font-weight:bold;margin-left:0pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >“Revenue from Contracts with Customers,”</font><font style='font-family:Times New Roman;font-size:10pt;' > a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in U.S. GAAP. Under this standard, revenue will be re</font><font style='font-family:Times New Roman;font-size:10pt;' >cognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. At its July 2015 meeting, the FASB agreed to defer </font><font style='font-family:Times New Roman;font-size:10pt;' >the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar year-end public entities. The Company is assessing the new standard and has not yet determined the impact to the consolida</font><font style='font-family:Times New Roman;font-size:10pt;' >ted financial statements. </font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In April 2015, the FASB issued ASU 2015-03, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update requires debt issuance costs related to a recognized debt liabili</font><font style='font-family:Times New Roman;font-size:10pt;' >ty to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability, instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rat</font><font style='font-family:Times New Roman;font-size:10pt;' >e. The update requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015.  Early adoption is permitted for financial statements that have not been previousl</font><font style='font-family:Times New Roman;font-size:10pt;' >y issued. The Company is evaluating the impact of ASU 2015-03 on its consolidated financial statements and the possibility of early adoption by the Company.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In July 2015, the FASB issued ASU 2015-11, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Simplifying Measurement of Inventory</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update requir</font><font style='font-family:Times New Roman;font-size:10pt;' >es measurement of most inventory “at the lower of cost and net realizable value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured under the last-in, first-out (LIFO) method or the retail inven</font><font style='font-family:Times New Roman;font-size:10pt;' >tory method (RIM). ASU 2015-11 requires prospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016.  Early adoption is permitted for financial statements that have not</font><font style='font-family:Times New Roman;font-size:10pt;' > been previously issued. The Company is evaluating the impact of ASU 2015-11 on its consolidated financial statements and the possibility of early adoption by the Company.</font></p></div>
CY2015Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	26181	shares
CY2014Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	31116	shares
CY2015Q2	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.08
CY2014Q2	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.2
	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.21
	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.19
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5169376	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2578743	shares
CY2015Q2	hbio	Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan	2500000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	17508929	shares
CY2015Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	80000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	100000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	32000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD

Files In Submission

Name	View Source	Status
0001171843-15-004444-index-headers.html	Edgar Link	pending
0001171843-15-004444-index.html	Edgar Link	pending
0001171843-15-004444.txt	Edgar Link	pending
0001171843-15-004444-xbrl.zip	Edgar Link	pending
exh_101.htm	Edgar Link	pending
exh_102.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gff10q_080615.htm	Edgar Link	pending
hbio-20150630.xml	Edgar Link	completed
hbio-20150630.xsd	Edgar Link	pending
hbio-20150630_cal.xml	Edgar Link	unprocessable
hbio-20150630_def.xml	Edgar Link	unprocessable
hbio-20150630_lab.xml	Edgar Link	unprocessable
hbio-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

2015 Q2 Form 10-Q Financial Statement

#000117184315004444 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO HARVARD BIOSCIENCE INC Stock $hbio

2015 Q2 Form 10-Q Financial Statement

#000117184315004444 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio